Ex-Warp Speed vaccine leader nabs NextGen funds for ModeX Therapeutics’ Covid-19 antibodies
A former leader of Operation Warp Speed’s vaccines effort, which led to a quick rollout of Covid jabs, is getting federal funding for his biotech’s work on the next generation of Covid therapeutics.
As part of the US government’s $5 billion Project NextGen, John Mascola’s ModeX Therapeutics will receive an initial $59 million to get a multispecific antibody into and through a Phase I trial as a potential tool for thwarting future SARS-CoV-2 variants. Mascola joined the OPKO Health-owned ModeX in 2022 as chief scientific officer after steering Warp Speed’s vaccine work and serving as director of the NIH’s Vaccine Research Center.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.